Entyvio Pathway® Privacy Notice

Last updated June 2023

This Privacy Notice explains what type of personal data we may collect from you and how we use it when you enrol in the Entyvio Pathway Program (the "Program").

The Program is a free service provided to you by Takeda and managed by IQVIA Solutions Australia Pty Ltd, trading as Ascott Sales Integration Pty Ltd ("Ascott”, "Provider", "we"). The Program aims to provide support for patients who have been prescribed Entyvio (vedolizumab) for Crohn’s disease or ulcerative colitis, and who are living in Australia. The Program offers delivery of medical supplies, home medication administration, care coordination, SMS and/or email treatment adherence reminders, self-injection education, disease state resources and program coordinator support.

How your personal data is collected, used, and stored

We collect and use personal data about you as may be required for the purposes of the Program, and to respond to or fulfil your requests. The personal data we may collect includes, but is not limited to, your contact information, delivery address, treatment, and treatment schedule, and any other information relevant to your participation in the Program. The personal data may be provided by you, or collected from healthcare professionals involved in your treatment, including your treating doctor, nurses, pharmacists, or your health insurer. We may not be able to provide you services under the Program if your personal data is not collected.

Information about your participation in the Program and healthcare needs may be shared with others, such as the healthcare professionals involved in your treatment, health insurer or the partners we work with to provide you this Program and the services under it. We may also use or disclose your personal data as needed to comply with regulatory requirements. This includes reporting of safety information to relevant regulatory authorities and/or Takeda.

Information about you will only be shared with Takeda in de-identified, aggregated reports for the purpose of Program administration and review, monitoring, measurement of treatment efficacy in relation to clinical trial results, measurement of treatment persistence, and health technology assessment purposes. Otherwise, Takeda will generally not be provided access to your personal data, unless required by law, or if necessary to ensure the integrity and continued provision of the Program. Information on how Takeda processes personal data is available at www.takeda.com/privacy-notice.

We store your personal data in Australia. The sharing of personal data as described above may involve transfers to other countries. The data protection and privacy laws in such countries may provide a different level of protection. We will put in place appropriate safeguards to protect personal data in connection with such transfers.

How long is my personal data retained?

Your personal data will be retained by Ascott for at least seven years, or as required by applicable law, after you have ended your participation in the Program or after the Program has ended, whichever is shortest. After this period, your personal data will be securely destroyed.

Your rights regarding your personal data

You can request access to your personal data. You may correct errors or request that your personal data be erased or make a privacy complaint. Contact our IQVIA Chief Privacy Officer at PrivacyOfficer@IQVIA.com who will respond to your request within the timeframes required by applicable laws and/or as soon as reasonable.